Wegovy is FDA-approved for weight loss. Ozempic is FDA-approved for type 2 diabetes treatment, but may be prescribed for weight loss.
*Free to end users subject to insurance and copays eligibility to be determined at time of visit.
*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs and arms in the first month.
These patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical.
Your results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. MEDVi patients typically result in 1-2 lbs per week weight loss in 4 weeks, involving a healthy diet and exercise changes. Consult a healthcare professional before using medication or starting any weight loss program.
*Based on the average weight loss in three 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity. See details.
Medication is included in the cost of the MEDVi Program.
Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy® ,Ozempic®), and products displayed on this Internet site are protected and belong to their respetive owners.
Medical treatment is provided by “MEDVi Affiliated P.C.s,” an affiliated network for medical professional corporations and associations.